Artesunate+Sulfadoxine-Pyrimethamine for the Treatment of Uncomplicated Falciparum Malaria
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
In Afghanistan, studies over the past 15 years have shown a high degree of Plasmodium
falciparum resistance to chloroquine (80%) and more recently an increasing degree of
resistance to sulfadoxine-pyrimethamine monotherapy (12%). In 2003 the high failure rate of
chloroquine against falciparum malaria led the national malaria treatment programme to switch
its recommended first line drug treatment for uncomplicated Plasmodium falciparum malaria to
artemisinin-based combination therapy (ACT) in the form of
Artesunate/Sulfadoxine-Pyrimethamine (AS+SP). Second line drug treatment is oral quinine (7
days). The aim of this study is to conduct ongoing monitoring of the efficacy of the new
combination against P. falciparum in a group of sentinel sites in Afghanistan.
Details
Lead Sponsor:
University of Oxford
Collaborators:
National Malaria and Leishmaniasis Control Program, Afghanistan World Health Organization
Treatments:
Artemisinins Artesunate Fanasil, pyrimethamine drug combination Pyrimethamine Sulfadoxine